GlassScriptPhysician profile
Sarah E Eccles-Brown
NPI 1750542791
$8,769.61
in general payments reported to CMS, 2019-2025
33 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,106 · 2020: $91.31 · 2021: $998 · 2022: $1,278 · 2023: $1,645 · 2024: $1,327 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,278 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,278.33 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,243.81 | 2019-2025 | Clareon, Tryptyr, Clareon Panoptix Pro |
| Abbvie INC. | $1,245.43 | 2021-2025 | Durysta |
| Sight Sciences, INC. | $595.97 | 2020-2024 | Omni Surgical System |
| Ocular Therapeutix, INC. | $427.10 | 2019-2023 | Dextenza |
| Bausch & Lomb Americas INC. | $414.05 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Amgen INC. | $386.35 | 2019-2025 | Tepezza |
| Regeneron Healthcare Solutions, INC. | $314.14 | 2023-2025 | Eylea Hd, Eylea |
| Horizon Therapeutics Plc | $273.01 | 2022-2023 | Tepezza |
| Allergan, INC. | $260.28 | 2019-2021 | |
| Glaukos Corporation | $231.84 | 2021-2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $196.69 | 2019-2021 | |
| Dompe US, INC. | $193.25 | 2024-2025 | Oxervate |
| Astellas Pharma US INC | $188.03 | 2023-2025 | Izervay |
| Merz North America, INC. | $172.66 | 2023 | Xeomin |
| New World Medical,INC. | $141.84 | 2025 | Clearpath, Kahook Dual Blade, Via360 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $138.92 | 2021-2025 | Cequa |
| Alimera Sciences, INC. | $127.30 | 2021 | |
| Eyepoint US, INC. | $124.97 | 2022 | |
| Revance Therapeutics, INC. | $123.68 | 2024 | Daxxify |
| Biohaven Pharmaceutical Holding Company LTD. | $117.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $111.81 | 2021 | |
| Oyster Point Pharma, INC. | $108.70 | 2022-2025 | Tyrvaya, Ryzumvi |
| Lilly USA, LLC | $89.33 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $72.75 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $71.43 | 2021-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $69.55 | 2019-2023 | |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Aerie Pharmaceuticals, INC. | $59.67 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $59.11 | 2024-2025 | Xdemvy |
| Rayner Intraocular Lenses Limited | $58.64 | 2024-2025 | Omidria |
| Harrow Eye, LLC | $38.46 | 2024-2025 | Vevye |
| Rxsight INC | $24.84 | 2022 | |
| Genentech USA, INC. | $23.80 | 2023 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Eccles-Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.